Pediatric monoclonal antibody trials remain concentrated in wealthier health systems
Pediatric monoclonal antibody research is expanding in theory, but the trial record tells a far narrower story. A cross-sectional analysis of ClinicalTrials.gov found 1,863 mAb trials that permitted pediatric enrollment, yet only 239 trials, or 12.8%, enrolled children exclusively. The gap between drug development potential and actual pediatric access is especially stark in global distribution: high-income countries hosted more than 200 times as many trials as low-income countries. For a drug class used against cancer, autoimmune disease, and infection, that imbalance shapes who gets studied, who gets treated, and which diseases receive scientific attention.
The issue is not simply where trials happen. It is also which children are invited into them, which conditions are prioritized, and whether the resulting evidence can be trusted and reused.
A small pediatric core inside a much larger adult-dominated pipeline
The registry data make clear that pediatric enrollment often sits at the margins of a broader development program rather than serving as the main design target. Most studies that allowed child participation were not pediatric-specific, meaning children were being included within trials largely built around broader populations. That pattern matters because dose selection, immune maturation, safety monitoring, and endpoint choice all differ in childhood. An antibody that behaves predictably in adults may not map neatly onto a child’s pharmacokinetic or disease profile, especially when organ development and immune system activity are still changing.
Only 239 trials were limited to pediatric populations. That is a small footprint for a biologic class that now touches multiple specialties and disease states. Pediatric drug development depends on deliberately structured enrollment, not incidental inclusion. When trials are not designed with children in mind from the outset, the result is often delayed labeling, limited dosing certainty, and clinical caution at the bedside.
Infectious disease trials were scarce, and neglected conditions were largely absent
Among all mAb trials permitting pediatric enrollment, only 168 trials, or 9.0%, targeted an infectious disease indication. Bacterial, fungal, and neglected tropical diseases were especially underrepresented. The imbalance is clinically important because infection remains a major global cause of pediatric morbidity, yet the antibody development pipeline appears heavily tilted toward other therapeutic areas.
This distribution reflects more than scientific preference. Monoclonal antibodies are expensive to develop and complex to deliver, and those barriers tend to steer research toward markets with strong commercial returns and advanced trial infrastructure. Diseases that disproportionately affect children in lower-resource settings do not attract the same development pressure, even when the biological rationale for passive immunotherapy is compelling. In practical terms, the children who might benefit most from a targeted antibody are often the least likely to be represented in the evidence base.
Geographic concentration points to structural inequity in trial access
The regional pattern was one of the clearest findings in the dataset. Trials conducted in high-income countries outnumbered those in low-income countries by more than 200-fold. Such a gap cannot be explained by biology alone. It points to differences in research infrastructure, regulatory capacity, sponsor priorities, site readiness, and access to specialized laboratory and pharmacy support.
For pediatric trials, the consequences are immediate. A protocol developed in the Global North may not be feasible in settings where children present later in disease, where competing health burdens complicate follow-up, or where trial sites have limited staffing and fewer opportunities to support long-duration biologic studies. The result is an evidence base that may be robust in places with the least disease burden and weakest where need is greatest.
Termination often followed low accrual, not lack of scientific plausibility
Trial attrition was another recurring theme. Low patient accrual and trial termination were the most commonly cited reasons for stopping studies. In pediatric research, accrual problems are not a trivial administrative issue. They can signal narrow eligibility criteria, rare disease prevalence, family hesitation, burdensome visit schedules, or site networks that are too small to support enrollment.
Low accrual also distorts the scientific record. A trial that stops early leaves behind unanswered dosing and safety questions, but it can still consume time, funding, and institutional effort. In children, where each study carries additional ethical scrutiny, premature termination can slow the path to reliable evidence for years. The biological promise of a monoclonal antibody does not matter if the trial cannot recruit the population it intends to help.
Transparency gaps limit reuse of the existing evidence base
The registry review also exposed a substantial transparency problem. Fewer than one third of trials posted results, and only a small fraction made study protocols, statistical analysis plans, and informed consent forms publicly available, despite mandatory disclosure requirements. That shortfall weakens the value of every completed study. Without results posting, negative or neutral findings can disappear from practical use. Without protocols and statistical plans, readers cannot verify whether analyses matched the original design. Without consent forms, investigators and ethics committees lose a key window into how pediatric risk was explained to families.
Transparency in pediatric research is not just an administrative ideal. It is the mechanism that allows clinicians, regulators, and families to judge whether a trial was conducted fairly and interpreted honestly. When disclosure is incomplete, the field loses reproducibility and confidence at the same time.
Policy choices will shape whether pediatric antibody research expands or stagnates
This analysis does not argue against monoclonal antibodies in children. It argues for a different development model. Pediatric mAb research needs wider geographic participation, better support for recruitment, and stronger adherence to disclosure standards. It also needs greater attention to infections, particularly diseases that remain underrepresented in commercial development pipelines.
The registry data provide a concrete map of where the field has failed to diversify. They also offer a route for funders and regulators: expand trial networks beyond the Global North, prioritize pediatric-specific protocols rather than incidental enrollment, and enforce the public posting of results and core regulatory documents. Without those changes, mAb research will continue to advance in a way that is scientifically sophisticated but globally uneven.
The evidence base is large in registration terms and thin where children actually need it most.